A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy.
Aspergillus
Central nervous system (CNS)
Chronic lymphocytic leukemia (CLL)
Ibrutinib
Invasive fungal infection (IFI)
Journal
Medical mycology case reports
ISSN: 2211-7539
Titre abrégé: Med Mycol Case Rep
Pays: Netherlands
ID NLM: 101598259
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
20
11
2019
revised:
02
12
2019
accepted:
04
12
2019
entrez:
28
12
2019
pubmed:
28
12
2019
medline:
28
12
2019
Statut:
epublish
Résumé
Ibrutinib has revolutionized the treatment of chronic lymphoid malignancies. Despite its success, ibrutinib has been linked with several reports of invasive fungal infections. We present a case of CNS aspergillosis in a CLL patient on first line ibrutinib therapy. We summarize existing case reports and case series of invasive aspergillosis in patients on ibrutinib, the pathogenesis of invasive aspergillosis, and discuss the clinical controversies regarding anti-fungal prophylaxis in this population.
Identifiants
pubmed: 31879587
doi: 10.1016/j.mmcr.2019.12.007
pii: S2211-7539(19)30120-4
pmc: PMC6920281
doi:
Types de publication
Case Reports
Langues
eng
Pagination
17-21Subventions
Organisme : NIAID NIH HHS
ID : T32 AI100851
Pays : United States
Informations de copyright
© 2019 Published by Elsevier B.V. on behalf of International Society for Human and Animal Mycology.
Déclaration de conflit d'intérêts
JP discloses the following consulting/advisory committee/research grants: Astellas, Merck, F2G, Cidara, Pfizer, Scynexis, Viamet, Amplyx, Vical, Matinas, Minnetronix. DB discloses the following consulting/advisory committee/research grants: AbbVie, ArQule, AstraZeneca, BeiGene, DTRM, Genentech, Juno, MEI Pharma, Novartis, Pharmacyclics, Teva, TG Therapeutics, Tolero, Verastem. JM, EE, SW and JS have nothing to disclose.
Références
EMBO Mol Med. 2015 Jan 30;7(3):240-58
pubmed: 25637383
Blood. 2018 Nov 1;132(18):1985-1988
pubmed: 30021784
N Engl J Med. 2016 Apr 21;374(16):1593-4
pubmed: 27096597
Lancet Oncol. 2016 Feb;17(2):200-211
pubmed: 26655421
Cancer Cell. 2017 Jun 12;31(6):833-843.e5
pubmed: 28552327
N Engl J Med. 2015 Dec 17;373(25):2425-37
pubmed: 26639149
Clin Cancer Res. 2017 May 1;23(9):2154-2158
pubmed: 27797975
Leuk Lymphoma. 2017 Dec;58(12):2981-2982
pubmed: 28554246
Mycotoxin Res. 2018 Nov;34(4):257-268
pubmed: 30006720
Blood. 2018 Nov 1;132(18):1869-1870
pubmed: 30385492
J Infect. 2012 Nov;65(5):453-64
pubmed: 22898389
Haematologica. 2019 Jun 6;:null
pubmed: 31171644
Medicine (Baltimore). 2000 Jul;79(4):250-60
pubmed: 10941354
Clin Infect Dis. 2018 Aug 16;67(5):687-692
pubmed: 29509845
Med Mycol Case Rep. 2019 Feb 28;24:27-29
pubmed: 30899641
Mycoses. 2019 Dec;62(12):1140-1147
pubmed: 31520441
Clin Infect Dis. 2018 Jan 6;66(1):140-148
pubmed: 29029010
Medicine (Baltimore). 2012 Nov;91(6):328-36
pubmed: 23117848
Med Mal Infect. 2018 Jun;48(4):294-297
pubmed: 29402474
Blood. 2018 Apr 26;131(17):1955-1959
pubmed: 29437588